Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures

被引：9

作者：

Thoueille, Paul ^{[1
,2
]}

Cavassini, Matthias ^{[2
,3
]}

Guidi, Monia ^{[1
,2
,4
,5
]}

Buclin, Thierry ^{[1
,2
]}

Girardin, Francois R. ^{[1
,2
]}

Decosterd, Laurent A. ^{[1
,2
]}

Marzolini, Catia ^{[1
,6
,7
,8
,9
]}

机构：

[1] Lausanne Univ Hosp, Dept Lab Med & Pathol, Serv & Lab Clin Pharmacol, Lausanne, Switzerland

[2] Univ Lausanne, Lausanne, Switzerland

[3] Lausanne Univ Hosp, Dept Med, Serv Infect Dis, Lausanne, Switzerland

[4] Lausanne Univ Hosp, Ctr Res & Innovat Clin Pharmaceut Sci, Lausanne, Switzerland

[5] Univ Lausanne, Univ Geneva, Inst Pharmaceut Sci Western Switzerland, Geneva, Switzerland

[6] Univ Basel, Univ Hosp Basel, Div Infect Dis & Hosp Epidemiol, Basel, Switzerland

[7] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool, England

[8] Lausanne Univ Hosp, Dept Lab Med & Pathol, Serv & Lab Clin Pharmacol, Rue Bugnon 17, Lausanne, Switzerland

[9] Univ Lausanne, Rue Bugnon 17, Lausanne, Switzerland

来源：

OPEN FORUM INFECTIOUS DISEASES | 2024年 / 11卷 / 02期

基金：

瑞士国家科学基金会;

关键词：

cabotegravir; guidance; long-acting; rilpivirine; TDM; ADULTS;

D O I：

10.1093/ofid/ofae023

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The interpretation of long-acting cabotegravir and rilpivirine concentrations is complicated by the lack of consensus on the threshold to consider. Building on real-world therapeutic drug monitoring data and documented virologic failures, this article provides a reappraisal of the existing thresholds and guidance for the interpretation of cabotegravir and rilpivirine concentrations. There is no established threshold for the interpretation of long-acting cabotegravir/rilpivirine concentrations. Building on real-world TDM data and documented virologic failures, this article provides a reappraisal of the existing thresholds, and guidance for the interpretation of cabotegravir and rilpivirine concentrations.

引用

页数：4

共 50 条

[1] Real-world data on long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror Phase 3 results
Serris, Alexandra
Ferre, Valentine Marie
Le Hingrat, Quentin
Bachelard, Antoine
Charpentier, Charlotte
Exarchopoulos, Marina
Damond, Florence
Phung, Bao-Chau
Landman, Roland
Yazdanpanah, Yazdan
Descamps, Diane
Joly, Veronique
Peytavin, Gilles
Ghosn, Jade
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (11) : 2932 - 2938
[2] Long-acting cabotegravir/rilpivirine for HIV-1 treatment: real-world evaluation of barriers to implementation
Wood, Brian R.
Kassaye, Seble G.
Gerstoft, Jan
AIDS, 2023, 37 (04) : 689 - 691
[3] Real world use of long-acting cabotegravir and rilpivirine in a HIV centre in Hong Kong
Chan, M. C. J.
Chik, S. H. T.
Lamb, S. S.
Choi, Y. C. C.
Lau, W. T. A.
Leung, C. S. E.
To, P. Y. L.
Lau, P. L. D.
Tsang, T. Y. O.
HIV MEDICINE, 2023, 24 : 155 - 156
[4] Long-acting cabotegravir and rilpivirine in HIV individuals with a BMI over 30: a real-world study (RELATIVITY cohort)
Troya, Jesus
Morano, Luis
Ignacio Bernardino, Jose
Buzon Martin, Luis
Pedrero Tome, Roberto
Galindo Puerto, Maria Jose
Torralba, Miguel
Cabello Clotet, Noemi
Garcia Lopez, Maria
Lope, Silvia
de Zarraga Fernandez, Miguel Alberto
Cabello, Alfonso
Aguilera Garcia, Maria
Cecilio, Alvaro
Diaz de Santiago, Alberto
Garcinuno Jimenez, Maria Angeles
Bernal, Enrique
Lopez Caballero, Maria Teresa
Calderon Hernaiz, Ruth
Vivancos Gallego, Maria Jesus
Omiste Sanvicente, Teresa
Ferreira Pasos, Eva
Losa Garcia, Juan Emilio
Soler Gonzalez, Josefa Francisca
Antonia Sepulveda, Maria
Garcia Navarro, Maria del Mar
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 92 - 93
[5] Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort
Michael G. Sension
Laurence Brunet
Ricky K. Hsu
Jennifer S. Fusco
Quateka Cochran
Christine Uranaka
Gayathri Sridhar
Vani Vannappagari
Jean Van Wyk
Lewis McCurdy
Michael B. Wohlfeiler
Gregory P. Fusco
Infectious Diseases and Therapy, 2023, 12 : 2807 - 2817
[6] Effectiveness and timing of viral load measurement in real-world use of long-acting cabotegravir-rilpivirine in people with HIV
Fernandez-Hinojal, F.
de Gea Grela, A.
Martin-Carbonero, L.
Valencia, E.
Mican, R.
Busca, C.
Ramos, L.
Arribas, J. R.
Gonzalez-Garcia, J.
Bernardino, J. I.
Montes, M. L.
HIV MEDICINE, 2023, 24 : 119 - 120
[7] Cabotegravir plus Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort
Sension, Michael G.
Brunet, Laurence
Hsu, Ricky K.
Fusco, Jennifer S.
Cochran, Quateka
Uranaka, Christine
Sridhar, Gayathri
Vannappagari, Vani
Van Wyk, Jean
Mccurdy, Lewis
Wohlfeiler, Michael B.
Fusco, Gregory P.
INFECTIOUS DISEASES AND THERAPY, 2023, 12 (12) : 2709 - 2724
[8] Process evaluation and early outcomes of real-world implementation of a pharmacist-driven cabotegravir/rilpivirine long-acting injectable initiative
Derrick, Caroline B.
Magee, Matthew
Tsai, Y. Vivian
Pizzuti, Morgan E.
Parker, Sarah
Lucas, Omar
Taylor, Kara
Albright, Raeghan
Langehans, Briley
Schreiber, Danny
Guest, Georgia
Ahuja, Divya
Weissman, Sharon
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2024,
[9] Unconventional use of injectable long-acting cabotegravir and rilpivirine against HIV-1 in PWH in clinical need: 52 weeks real-world data
Iannone, Valentina
Rossotti, Roberto
Bana, Nicholas Brian
Cavazza, Gabriele
D'Amico, Federico
Lombardi, Francesca
Salvo, Pierluigi Francesco
Baldin, Gianmaria
Di Giambenedetto, Simona
Bernacchia, Dario
Pagani, Gabriele
Borghetti, Alberto
Rusconi, Stefano
BMC INFECTIOUS DISEASES, 2025, 25 (01)
[10] Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
Fernandez, Cristina
van Halsema, Clare L.
HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2019, 11 : 179 - 192

← 1 2 3 4 5 →